Madison, WI – Voximetry, a pioneer in personalized dosimetry for radiopharmaceutical therapy (RPT), today announced changes to its leadership team in preparation for global commercial growth, signaling a major milestone in the company’s evolution. Having led the successful development and commercialization of Voximetry, Dr. Sue Wallace moves to Executive Chair as Andreas Schulte, following his oversight of international markets, shifts to CEO.
“Voximetry’s strategic objectives are to provide solutions that drive transformational change in the development of radiotherapeutics and the delivery of optimized clinical care to patients,” said Dr. Wallace. “Its corporate strategy and key partnerships will be my primary focus going forward. I’m incredibly proud of this young company’s maturity in building a world-class team and trusted brand. Based on the global momentum Andreas has generated, and his technical mastery of treatment planning and RPT dosimetry, I am very confident he is the right CEO to lead Voximetry forward.”
Dr. Wallace joined Voximetry as CEO in August 2020. Under her leadership the company rapidly achieved Food and Drug Administration (FDA) market clearance for Torch® Dose Assessment software − a best-in-class technology − and launched a high-growth Dosimetry Services business for RPT clinical trials. As Executive Chair, she will remain engaged in day-to-day management of the Dosimetry Services business growth.
Key to the company’s expansion is CE Mark approval, which will open access to European and Middle Eastern markets, and serve as a gateway to Asia Pacific territories. With multiple international distribution agreements and a partnership with Siemens Healthineers, Voximetry is well positioned to rapidly expand.
“Sue will remain a close partner to ensure a seamless transition while directly contributing to Voximetry’s business objectives,” said Andreas Schulte. “We have ambitious global growth targets over the next several years and will continue building market-leading technology and services based on RPT scientific insight and discovery – as we have done from the start.”
Mr. Schulte has extensive international business experience in growing new markets, including in Radiation Oncology and Theranostics. He joined Voximetry in 2021 and has served as VP of International Business Development, EMEA/APAC General Manager, and Chief Operating Officer. Schulte will build on his relationships with key opinion leaders, regulators, policymakers, investors, and professional societies to advocate for RPT treatment optimization using image-based, quantitative advanced dosimetry methods both in RPT clinical trials and in clinical practice settings.
“With ongoing market momentum, global interest in Voximetry’s solutions and a strong collaboration network, we are poised for rapid growth,” said Schulte. “I feel very confident that by maintaining operational excellence and a commitment to technology-forward innovation, Voximetry will lead the way as a trusted provider of quantitative RPT solutions across the industry.”
The timing of Voximetry’s global expansion is supported by rapid and increasing growth across the field of theranostics. The FDA’s clearance of PLUVICTO® for earlier treatment stages of prostate cancer is expected to fuel adoption of radiopharmaceutical therapies for a growing number of patients. This is supported by initiatives led by the European Association of Nuclear Medicine (EANM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI), and the American Society for Radiation Oncology (ASTRO) which seek to further strengthen and align efforts to grow clinical theranostics programs. In parallel, new regulatory guidance documents being developed by the FDA and European Medicines Agency (EMA) are anticipated to put dosimetry at the heart of the development process for new RPTs.
About Voximetry
Voximetry is committed to enabling personalized and effective theranostic treatment options for patients worldwide through wide-ranging collaboration, deep scientific expertise, and technology-forward progress. Based in Madison, Wisconsin, Voximetry is a Healthtech software and services company pioneering advanced dosimetry to enable patient-specific radiopharmaceutical therapy (RPT) in cancer patients.
For media inquiries, please contact marketing@voximetry.com.
www.voximetry.com